Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS)

被引：0
|
作者：
Jabbour, Elias [1 ]
Kantarjian, Hagop M. [1 ]
Wang, Xuemei [1 ]
Abruzzo, Lynne V. [1 ]
Cornelison, A. Megan [1 ]
O'Brien, Susan [1 ]
Ravandi, Farhad [1 ]
Kadia, Tapan [1 ]
Borthakur, Gautam [1 ]
Estrov, Zeev [1 ]
Cortes, Jorge E. [1 ]
Garcia-Manero, Guillermo [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1624 / 1624
页数：1
相关论文
共 50 条
  • [1] An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Goede, Jeroen Simon
    Guerci-Bresler, Agnes
    Delforge, Michel
    Oliva, Esther Natalie
    Mayer, Jiri
    Badre, Sejal
    Mehta, Bhakti
    Brandao, Cisio De Oliveira
    [J]. BLOOD, 2017, 130
  • [2] Cytogenetic Evolution (CE) In Patients (pts) with Low and Intermediate Risk Myelodysplastic Syndromes (MDS) Is Associated with Poor Prognosis
    Li, Liunan
    Jabbour, Elias
    Borthakur, Gautam
    Faderl, Stefan
    Kadia, Tapan
    Ravandi, Farhad
    Pierce, Sherry A.
    Wierda, William G.
    Abruzzo, Lynne V.
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2010, 116 (21) : 1212 - 1212
  • [3] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. HAEMATOLOGICA, 2017, 102 : 484 - 484
  • [4] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. LEUKEMIA RESEARCH, 2017, 55 : S29 - S30
  • [5] Identification of Poor Risk Patients in Low and Intermediate-1 (Int-1) IPSS MDS with the New Ipssr Index and Comparison with Other Prognostic Indexes. A Study by the Spanish Group of MDS (GESMD)
    Valcarcel, David
    Sanz, Guillermo
    Ortega, Margarita
    Nomdedeu, Benet
    Luno, Elisa
    Diez-Campelo, Maria
    Teresa Ardanaz, M.
    Pedro, Carmen
    Montoro, Julia
    Collado, Rosa
    Andreu, Rafa
    Marco, Victor
    Teresa Cedena, Maria
    de Paz, Raquel
    Tormo, Mar
    Xicoy, Blanca
    Ramos, Fernando
    Bargay, Joan
    Gonzalez, Bernardo
    Brunet, Salut
    Antonio Muaoz, Juan
    Gomez, Valle
    Bailen, Alicia
    Sanchez', Joaquin
    Vallespi, Teresa
    [J]. BLOOD, 2012, 120 (21)
  • [6] A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Oliva, Esther N.
    Goede, Jeroen S.
    Delforge, Michel
    Mayer, Jiri
    Slama, Borhane
    Badre, Sejal
    Gasal, Eduard
    Mehta, Bhakti
    Franklin, Janet
    [J]. BLOOD, 2016, 128 (22)
  • [7] ACQUISITION OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH IPSS LOW AND INTERMEDIATE-1 RISK. STUDY FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROME
    Merchan, B.
    Ortega, M.
    Llamas-Poyato, M. J.
    Cortes, M.
    Arnan, M.
    Cervero, C.
    Montoro, J.
    Gimenez, T.
    Lopez, M.
    Arenillas, L.
    Valcarcel, D.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S136 - S136
  • [8] Diagnostic procedures and treatment of patients with Myelodysplastic Syndromes (MDS) of low and intermediate-1 risk. Results of the outpatient MDS registry
    Schmitz, S.
    Boettger, I
    Schnell, R.
    Lerchenmueller, C.
    Sauer, A.
    Severin, K.
    Germing, U.
    Steinmetz, H. T.
    [J]. ONKOLOGIE, 2012, 35 : 148 - 148
  • [9] Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Xiao, Lianchun
    Najla, Al Ali
    Mishra, Asmita
    Padron, Eric
    Lancet, Jeffrey E.
    Bryan, Jeffery
    Prescott, Hillary
    Steensma, David P.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    List, Alan
    Kantarjian, Hagop M.
    Komrokji, Rami S.
    [J]. BLOOD, 2013, 122 (21)
  • [10] Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κB Activation
    Randhawa, Jasleen K.
    Jabbar, Kausar Jabeen
    Kadia, Tapan
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Hearn, Katherine
    Bueso-Ramos, Carlos E.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2014, 124 (21)
12345